NCT05358899

Brief Summary

cTBS is a promising novel intervention, which has strong potential on moderating disease syndrome. However, the most effective pattern of the cTBS is still under debate. Therefore, the investigators designed this randomized controlled clinical trial to evaluate the efficacy and safety of accelerated cTBS, with 1800 stimulation per session, on intervention to metabolic side effects in individuals with schizophrenia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable schizophrenia

Timeline
Completed

Started Jun 2022

Shorter than P25 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 3, 2022

Completed
29 days until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2023

Completed
Last Updated

November 21, 2022

Status Verified

November 1, 2022

Enrollment Period

6 months

First QC Date

April 28, 2022

Last Update Submit

November 17, 2022

Conditions

Keywords

schizophreniametabolic disturbancecTBSEvent related potentials

Outcome Measures

Primary Outcomes (2)

  • Change of body weight

    the change of participants weight

    from baseline to 6 weeks

  • Change of body mass index

    the change of participants BMI

    from baseline to 6 weeks

Secondary Outcomes (5)

  • Positive and Negative syndrome rating scale

    from baseline to 6 weeks

  • Three Factor Eating Questionnaire

    from baseline to 6 weeks

  • Barrat impulsiveness scale

    from baseline to 6 weeks

  • Self-Control Scale

    from baseline to 6 weeks

  • Food picture stimulation Event-related potentials

    from baseline to 6 weeks

Study Arms (2)

Real stimulation

EXPERIMENTAL

Participants in the real stimulation group will receive accelerated cTBS with 1800 stimulation per session for 10 consecutive days, 5 sessions per day with a gap at least one hour, 50 sessions in total. The stimulation will be conducted at left M1 area.

Device: accelerated theta burst stimulation

Sham stimulation

SHAM COMPARATOR

Participants in the sham stimulation group will receive the stimulation with coil vertical to the surface with other settings same as the real stimulation group.

Device: Sham stimulation

Interventions

cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).

Real stimulation

Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.

Sham stimulation

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients diagnosed with schizophrenia in accordance with DSM-5
  • BMI over 24
  • Accepting antipsychotics stable treatment for more then 2 months

You may not qualify if:

  • Diagnosed with other mental disease in accordance with DSM-5
  • Comorbid with other severe physiological disease
  • Used antipsychotic, antidepressants, mood stabilizer, or other psychoactive substances before
  • Drug or alcohol abuse
  • Pregnant or lactating Contraindication to rTMS

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Second Xiangya Hospital Central South University

Changsha, Hunan, 410000, China

RECRUITING

MeSH Terms

Conditions

SchizophreniaFeeding Behavior

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental DisordersBehavior, AnimalBehavior

Central Study Contacts

Renrong Wu, Prof

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The participants, care provider, investigator, and outcome assessor will be blind to the intervention except the treatment provider.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized Quadro-blind clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 28, 2022

First Posted

May 3, 2022

Study Start

June 1, 2022

Primary Completion

December 1, 2022

Study Completion

May 1, 2023

Last Updated

November 21, 2022

Record last verified: 2022-11

Locations